Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

Metal-based drugs that break the rules

(2016) Claire S. Allardyce et al.   DALTON TRANSACTIONS

Biodistribution of the novel anticancer drug sodium trans -[tetrachloridobis(1 H -indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action

(2016) Anna K. Bytzek et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism

(2016) Aleksandar Bijelic et al.   JOURNAL OF MEDICINAL CHEMISTRY

Linking the future of anticancer metal-complexes to the therapy of tumour metastases

(2015) Alberta Bergamo et al.   CHEMICAL SOCIETY REVIEWS

Noble metals in medicine: Latest advances

(2015) Serenella Medici et al.   COORDINATION CHEMISTRY REVIEWS

Albumin binding and ligand-exchange processes of the Ru(iii) anticancer agent NAMI-A and its bis-DMSO analogue determined by ENDOR spectroscopy

(2015) Michael I. Webb et al.   DALTON TRANSACTIONS

Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity

(2015) V. Novohradský et al.   DALTON TRANSACTIONS

Interaction of anticancer Ru(iii) complexes with single stranded and duplex DNA model systems

(2015) Domenica Musumeci et al.   DALTON TRANSACTIONS

An iridium(iii)-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent

(2015) Hai-Jing Zhong et al.   Chemical Science

Antagonizing STAT3 Dimerization with a Rhodium(III) Complex

(2014) Dik-Lung Ma et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels

(2014) Serena Pillozzi et al.   DALTON TRANSACTIONS

Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme

(2014) Luigi Messori et al.   DALTON TRANSACTIONS

Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer

(2014) Alberta Bergamo et al.   INVESTIGATIONAL NEW DRUGS

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

(2014) Suzanne Leijen et al.   INVESTIGATIONAL NEW DRUGS

NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

(2014) Robert Trondl et al.   Chemical Science

Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity

(2014) Zenita Adhireksan et al.   Nature Communications

Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study

(2013) Aviva Levina et al.   CHEMISTRY-A EUROPEAN JOURNAL

Interaction of Anticancer Ruthenium Compounds with Proteins: High-Resolution X-ray Structures and Raman Microscopy Studies of the Adduct between Hen Egg White Lysozyme and AziRu

(2013) Alessandro Vergara et al.   INORGANIC CHEMISTRY

Investigating the Ruthenium Metalation of Proteins: X-ray Structure and Raman Microspectroscopy of the Complex between RNase A and AziRu

(2013) Alessandro Vergara et al.   INORGANIC CHEMISTRY

EPR as a probe of the intracellular speciation of ruthenium(iii) anticancer compounds

(2013) Michael I. Webb et al.   Metallomics

Influence of an anti-metastatic ruthenium(iii) prodrug on extracellular protein–protein interactions: studies by bio-layer interferometry

(2013) Aviva Levina et al.   Inorganic Chemistry Frontiers

Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies

(2012) Orsolya Dömötör et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Transferrin–cisplatin specifically deliver cisplatin to HepG2 cells in vitro and enhance cisplatin cytotoxicity

(2012) Lian-Zhong Luo et al.   Journal of Proteomics

Molecular and Cellular Characterization of the Biological Effects of Ruthenium(II) Complexes Incorporating 2-Pyridyl-2-pyrimidine-4-carboxylic Acid

(2012) Vanessa Pierroz et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells

(2012) Jade B. Aitken et al.   Metallomics

The intracellular trafficking pathway of transferrin

(2011) Kristine M. Mayle et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(iii) complex NAMI-A by interactions with human serum albumin

(2011) Michael I. Webb et al.   DALTON TRANSACTIONS

Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: Passing the nanomolar barrier

(2011) Ludivine Fetzer et al.   DALTON TRANSACTIONS

Metal-based antitumour drugs in the post-genomic era: what comes next?

(2011) Gianni Sava et al.   DALTON TRANSACTIONS

Synthesis, structures, cellular uptake and apoptosis-inducing properties of highly cytotoxic ruthenium-Norharman complexes

(2011) Caiping Tan et al.   DALTON TRANSACTIONS

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs

(2011) Alberta Bergamo et al.   DALTON TRANSACTIONS

Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors

(2011) M.M. Henke et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro

(2011) Alethia A. Hostetter et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Impact of albumin on drug delivery — New applications on the horizon

(2011) Bakheet Elsadek et al.   JOURNAL OF CONTROLLED RELEASE

Approaching tumour therapy beyond platinum drugs

(2011) A. Bergamo et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Characterization of a Ruthenium(III)/NAMI-A Adduct with Bovine Serum Albumin that Exhibits a High Anti-Metastatic Activity

(2010) Mimi Liu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Ruthenium-based chemotherapeutics: are they ready for prime time?

(2010) Emmanuel S. Antonarakis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The X-ray Structure of the Adduct between NAMI-A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins

(2010) Angela Casini et al.   ChemMedChem

The status of platinum anticancer drugs in the clinic and in clinical trials

(2010) Nial J. Wheate et al.   DALTON TRANSACTIONS

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

(2010) Petra Heffeter et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

A categorization of metal anticancer compounds based on their mode of action

(2009) Teresa Gianferrara et al.   DALTON TRANSACTIONS

Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR

(2009) Naniye Cetinbas et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Recent developments in ruthenium anticancer drugs

(2009) Aviva Levina et al.   Metallomics

KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

(2008) Christian G. Hartinger et al.   CHEMISTRY & BIODIVERSITY

Characterisation of Cisplatin Binding Sites in Human Serum Proteins Using Hyphenated Multidimensional Liquid Chromatography and ESI Tandem Mass Spectrometry

(2008) Joanna Will et al.   ChemMedChem

Cellular Uptake, Cytotoxicity, and Metabolic Profiling of Human Cancer Cells Treated with Ruthenium(II) Polypyridyl Complexes [Ru(bpy)2(NN)]Cl2with NN=bpy, phen, dpq, dppz, and dppn

(2008) Ulrich Schatzschneider et al.   ChemMedChem

The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin

(2008) Malgorzata Brindell et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Ga3+ as a mechanistic probe in Fe3+ transport: characterization of Ga3+ interaction with FbpA

(2008) Katherine D. Weaver et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles

(2008) Felix Kratz   JOURNAL OF CONTROLLED RELEASE

Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(η6-p-cymene)Cl2(pta)]

(2008) Claudine Scolaro et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

Metal-Ligand Exchange Kinetics in Platinum and Ruthenium Complexes

(2008) By Jan Reedijk  

Catalytic organometallic anticancer complexes

(2008) S. J. Dougan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antitumour metal compounds: more than theme and variations

(2007) Michael A. Jakupec et al.   DALTON TRANSACTIONS

Influence of the anionic ligands on the anticancer activity of Ru(II)–dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors

(2007) Ioannis Bratsos et al.   JOURNAL OF INORGANIC BIOCHEMISTRY